Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreatic cancer.
Monitoring therapy response in pancreatic cancer (PDAC) remains challenging. The microbiome affects therapy efficacy, but its role in response prediction is unclear.
Monitoring therapy response in pancreatic cancer (PDAC) remains challenging. The microbiome affects therapy efficacy, but its role in response prediction is unclear.
What the study was
- Study design
- Cohort/Observational Study
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Eur J Cancer
Why it surfaced
Matched watchlist topic 'Precision oncology and genomic medicine'. Study design: Cohort/Observational Study. Score: 8/10 (N:3, R:3, D:1, P:1).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.